LATEST ARTICLES

Celyad’s Off-The-Shelf Cell Therapy CYAD-101 In Colorectal Cancer Dose-Escalation Phase 1 Trial

Celyad, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, has announced highlights from the company’s NKG2D-based CAR-T clinical candidates for...

Glaucoma And Brain Degeneration Linked In People With African Ancestry

A global research team led by scientists from Singapore and the United States has discovered new evidence that there is an underlying link between...

CENTOGENE And Pfizer Collaborating For Rare Disease Patients

CENTOGENE, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies,...

BioLife Solutions Expands The Product Line By Acquiring Custom Biogenic Systems

BioLife Solutions, Inc., a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the acquisition...

The Pulmonary Fibrosis Foundation’s PRECISIONS Study Awarded $22 Million Grant

The Pulmonary Fibrosis Foundation (PFF) has launched PRECISIONS, a study that aims to transform the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), by...

Discovery Life Sciences™ Acquires QualTek Molecular Laboratories

Discovery Life Sciences™ (Discovery) has acquired QualTek Molecular Laboratories (QualTek), a renowned provider of immunohistochemistry (IHC) services with CAP/CLIA-accredited and Good Laboratory Practice-(GLP) capable laboratories...

Premier Global Biological Materials Resource ATCC Celebrates Headquarter Building Expansion

ATCC has launched its second headquarters expansion with a ground-breaking ceremony in Manassas that celebrates its continued commitment to innovative science and to the...

The Ulysses Genome Project: An Inclusive Mediterranean Genome Reference Of 100,000 Individuals

Leading DNA sequencing company Dante Labs has announced its new Mediterranean Genome Project, Ulysses, which will sequence 100,000 human whole genomes in the next...

ImmunoQure And Memo Therapeutics Collaborate To Biobank Rare Disease Autoantibodies

ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases and Memo Therapeutics AG, a biotechnology company...

Biobanking Science: CRISPR Gene Editing to Treat Human Disease

This year has seen a flurry of good news about CRISPR gene editing clinical trials in human patients. CRISPR-Cas 9 is a gene editing...